Costimulation-adhesion blockade is superior to cyclosporine a and prednisone immunosuppressive therapy for preventing rejection of differentiated human embryonic stem cells following transplantation

Stem Cells

Volumn 31, Issue 11, 2013, Pages 2354-2363

  Huber, Bruno C ^a   Ransohoff, Julia D ^a   Ransohoff, Katherine J ^a   Riegler, Johannes ^a   Ebert, Antje ^a   Kodo, Kazuki ^a   Gong, Yongquan ^a   Sanchez Freire, Veronica ^a   Dey, Devaveena ^a   Kooreman, Nigel G ^a   Diecke, Sebastian ^a   Zhang, Wendy Y ^a   Odegaard, Justin ^a   Hu, Shijun ^a   Gold, Joseph D ^a   Robbins, Robert C ^a   Wu, Joseph C ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stanford California and Cofounder   (United States)

Author keywords

Costimulation blockade; Embryonic stem cells; Endothelial cells; Immune tolerance; Immunosuppressive drugs; Myocardial infarction

Indexed keywords

CYCLOSPORIN A; ENHANCED GREEN FLUORESCENT PROTEIN; FIREFLY LUCIFERASE; IMMUNOGLOBULIN; INTERLEUKIN 2; MUCIN; PREDNISONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CARDIOVASCULAR MAGNETIC RESONANCE; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; COSTIMULATION ADHESION THERAPY; DOWN REGULATION; EMBRYONIC STEM CELL; ENDOTHELIUM CELL; ENGRAFTMENT; FIBROBLAST; FLOW CYTOMETRY; GENE EXPRESSION; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REPORTER GENE; STEM CELL TRANSPLANTATION; T LYMPHOCYTE ACTIVATION; UPREGULATION;

COSTIMULATION BLOCKADE; EMBRYONIC STEM CELLS; ENDOTHELIAL CELLS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE DRUGS; MYOCARDIAL INFARCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CARDIOTONIC AGENTS; CELL DIFFERENTIATION; CYCLOSPORINE; EMBRYONIC STEM CELLS; ENDOTHELIAL CELLS; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED NOD; MICE, SCID; MYOCARDIAL INFARCTION; PREDNISONE; RANDOM ALLOCATION;

EID: 84887958536     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1501     Document Type: Article

References (42)

1. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature 2008; 453: 322-329. (Pubitemid 351693138)
2. Burridge PW, Keller G, Gold JD et al. Production of de novo cardio-myocytes: Human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 2012; 10: 16-28.
3. Pearl JI, Lee AS, Leveson-Gower DB et al. Short-term immunosup-pression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2011; 8: 309-317.
4. Swijnenburg RJ, Schrepfer S, Govaert JA et al. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci USA 2008; 105: 12991-12996.
5. Okita K, Nagata N, Yamanaka S. Immunogenicity of induced pluripo-tent stem cells. Circ Res 2011; 109: 720-721.
6. Swijnenburg RJ, Tanaka M, Vogel H et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005; 112:I166-172. (Pubitemid 41266669)
7. Koch CA, Geraldes P, Platt JL. Immunosuppression by embryonic stem cells. Stem Cells 2008; 26: 89-98.
8. Pearl JI, Kean LS, Davis MM et al. Pluripotent stem cells: Immune to the immune system? Sci Transl Med. 2012; 4: 164ps125.
9. Gu M, Nguyen PK, Lee AS et al. Microfluidic single-cell analysis shows that porcine induced pluripotent stem cell-derived endothelial cells improve myocardial function by paracrine activation. Circ Res 2012; 111: 882-893.
10. Narmoneva DA, Vukmirovic R, Davis ME et al. Endothelial cells promote cardiac myocyte survival and spatial reorganization: Implications for cardiac regeneration. Circulation 2004; 110: 962-968. (Pubitemid 39136214)
11. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199-210. (Pubitemid 37323205)
12. Ferrer IR, Wagener ME, Robertson JM et al. Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J Immunol 2010; 185: 2004-2008.
13. Ludwig TE, Levenstein ME, Jones JM et al. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 2006; 24: 185-187. (Pubitemid 43221701)
14. Hu S, Wilson KD, Ghosh Z et al. MicroRNA-302 increases reprogramming efficiency via repression of NR2F2. Stem Cells 2013; 31: 259-268.
15. Lian X, Hsiao C, Wilson G et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci USA 2012; 109:E1848-1857.
16. Sheikh AY, Huber BC, Narsinh KH et al. In vivo functional and tran-scriptional profiling of bone marrow stem cells after transplantation into ischemic myocardium. Arterioscler Thromb Vasc Biol 2012; 32: 92-102.
17. Riegler J, Cheung KK, Man YF et al. Comparison of segmentation methods for MRI measurement of cardiac function in rats. J Magn Reson Imaging 2010; 32: 869-877.
18. Zhang J, Wilson GF, Soerens AG et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009; 104:e30-41.
19. de Almeida P.E., van Rappard JR, Wu JC. In vivo bioluminescence for tracking cell fate and function. Am J Physiol Heart Circ Physiol. 2011; 301:H663-71.
20. Meyerrose TE, Herrbrich P, Hess DA et al. Immune-deficient mouse models for analysis of human stem cells. Biotechniques 2003; 35: 1262-1272. (Pubitemid 37517506)
21. Xiao YF, Min JY, Morgan JP. Immunosuppression and xenotransplan-tation of cells for cardiac repair. Ann Thorac Surg 2004; 77: 737-744. (Pubitemid 38186555)
22. Lee AS, Tang C, Rao M.S., et al. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med 2013; 9: 998-1004.
23. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7: 445-450. (Pubitemid 27508696)
24. Nicolls MR, Coulombe M, Yang H et al. Anti-LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-gamma or IL-4. J Immunol 2000; 164: 3627-3634. (Pubitemid 30169816)
25. Ford ML, Larsen CP. Translating costimulation blockade to the clinic: Lessons learned from three pathways. Immunol Rev 2009; 229: 294-306.
26. Kawai T, Andrews D, Colvin RB et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114. (Pubitemid 30082329)
27. Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: Current and emerging paradigms of care. Clin Ther 2011; 33: 679-707.
28. Patel JK, Kobashigawa JA. Cardiac transplant experience with cyclo-sporine. Transplant Proc 2004; 36: 323S-330S.
29. Ransohoff JD, Wu JC. Imaging stem cell therapy for the treatment of peripheral arterial disease. Curr Vasc Pharmacol 2012; 10: 361-373.
30. Stegagno M, Boyle LA, Preffer FI et al. Functional analysis of T cell subsets and clones in human renal allograft rejection. Transplant Proc 1987; 19: 394-397. (Pubitemid 17025415)
31. Jones RB, Ndhlovu LC, Barbour JD et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008; 205: 2763-2779.
32. Dardalhon V, Anderson AC, Karman J et al. Tim-3/galectin-9 pathway: Regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol 2010; 185: 1383-1392.
33. Freeman GJ, Casasnovas JM, Umetsu DT et al. TIM genes: A family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 2010; 235: 172-189.
34. Sanchez-Fueyo A., Tian J, Picarella D et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immu-nological tolerance. Nat Immunol 2003; 4: 1093-1101. (Pubitemid 37428037)
35. Fourcade J, Sun Z, Benallaoua M et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175-2186.
36. Monney L, Sabatos CA, Gaglia JL et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002; 415: 536-541. (Pubitemid 34130609)
37. Sakaguchi S, Sakaguchi N. Thymus and autoimmunity: Capacity of the normal thymus to produce pathogenic self-reactive T cells and conditions required for their induction of autoimmune disease. J Exp Med 1990; 172: 537-545. (Pubitemid 20248395)
38. Kingsley CI, Karim M, Bushell AR et al. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002; 168: 1080-1086. (Pubitemid 34094471)
39. Mirotsou M, Jayawardena TM, Schmeckpeper J et al. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol 2011; 50: 280-289.
40. Schwartz SD, Hubschman JP, Heilwell G et al. Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet 2012; 379: 713-720.
41. Garber K. Inducing translation. Nat Biotechnol 2013; 31: 483-486.
42. de Almeida P.E., Ransohoff JD, Nahid A et al. Immunogenicity of plu-ripotent stem cells and their derivatives. Circ Res 2013; 112: 549-561.